Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is April 23, 2024.
All times in Eastern Daylight Time.
-
Riassunto: ReNAgade Therapeutics annuncia due presentazioni alla 27a edizione del convegno annuale ASGCTCAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, un’azienda che sta mettendo a frutto l’illimitato potenziale dei farmaci a base di RNA, oggi ha annunciato la presentazione di un poster e ... more »
-
Resumen: ReNAgade Therapeutics anuncia presentaciones en la 27a reunión anual de ASGCTCAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, una compañía que desarrolla el potencial ilimitado de los medicamentos de ARN, ha anunciado hoy una presentación oral y de póster que desta... more »
-
Samenvatting: ReNAgade Therapeutics kondigt presentaties aan op de 27e jaarlijkse ASGCT-bijeenkomstCAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, een bedrijf dat het grenzeloze potentieel voor RNA-geneesmiddelen ontsluit, kondigde vandaag een mondelinge en posterpresentatie aan tijden... more »
-
ReNAgade Therapeutics annonce des présentations à la 27e réunion annuelle de l’ASGCTCAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, une société exploitant le potentiel illimité des médicaments à base d’ARN, a annoncé aujourd’hui une présentation orale et sur poster metta... more »
-
ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表CAMBRIDGE, Mass.--(BUSINESS WIRE)--(ビジネスワイヤ) -- RNA医薬品の無限の可能性にチャレンジする企業、ReNAgade Therapeuticsは、米国遺伝子細胞治療学会(ASGCT)で発表予定の口頭およびポスタープレゼンテーションの内容を発表しました。このプレゼンテーションでは、同社の包括的なRNA技術プラットフォームを裏付ける前臨床データが焦点と... more »
-
ReNAgade Therapeutics kündigt Präsentationen auf der 27. Jahrestagung der ASGCT anCAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, ein Unternehmen, das das grenzenlose Potenzial von RNA-Medikamenten erschließt, gab heute eine mündliche und eine Posterpräsentation bekann... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
Global Oriented Strand Board (OSB) Industry Report 2023-2030: North America and Europe Lead, Construction Sector Dominates - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "Oriented Strand Board (OSB) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Oriented Strand Board (OSB) Market t... more »
-
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 22.04.2024 GINC LN IE00BD842Y21 559,957.00 USD... more »
-
SES Share Buy Back - Repurchase ReportLUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Présentation agrégée par jour et par marché Nom de l'émetteur Code Identifiant de l'émetteur Jour de la transaction Code identifiant de l'instrum... more »
-
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 22.04.2024 FGBL.LN IE00BYTH6121 66,146.00 USD ... more »
-
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 22.04.2024 FKUD IE00BD9N0445 111,095.00 GBP... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
X-energy Awarded $148.5 Million Investment Tax Credit for First-of-a-Kind TRISO-X Fuel Fabrication FacilityOAK RIDGE, Tenn.--(BUSINESS WIRE)--X Energy, LLC (“X-energy”) has been awarded a $148.5 million tax credit for the construction by its wholly-owned subsidiary, TRISO-X LLC (“TRISO-X”), of a first-o... more »